Dapagliflozin as Monotherapy or Combination Therapy in Japanese Patients with Type 2 Diabetes: an Open-Label Study

INTRODUCTION: Dapagliflozin is a selective sodium glucose co-transporter 2 inhibitor that improves glycemic control and reduces body weight and systolic blood pressure in patients with type 2 diabetes mellitus (T2DM). Dapagliflozin is effective and well tolerated over 12–24 weeks in Japanese patient...

Descripción completa

Detalles Bibliográficos
Autores principales: Kaku, Kohei, Maegawa, Hiroshi, Tanizawa, Yukio, Kiyosue, Arihiro, Ide, Yumiko, Tokudome, Takuto, Hoshino, Yuji, Yang, Jisin, Langkilde, Anna Maria
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer Healthcare 2014
Materias:
Original Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4269643/
https://www.ncbi.nlm.nih.gov/pubmed/25341477
http://dx.doi.org/10.1007/s13300-014-0086-7

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4269643/
https://www.ncbi.nlm.nih.gov/pubmed/25341477
http://dx.doi.org/10.1007/s13300-014-0086-7

Ejemplares similares